拜恩泰科
102.09
Open
Market Cap
High
Low
Close
Volume
P/E Ratio
Div/Yield
About 拜恩泰科
BioNTech成立于2008年，专注于分子免疫疗法和基于生物标记物的诊断方法的开发。 公司将开创性的研究与尖端技术相结合，以开发用于癌症及其他领域的开创性疗法。公司在诊所证明这种方法的价值时，继续建立合作伙伴关系，制造和团队，以向全球患者提供个性化治疗。 从在德国美因茨的根源开始，公司就致力于成为全球领先的个性化抗癌药物生物技术公司。
Trade GPT
Similar Stocks
© 2025 Rockalpha Limited. All Rights Reserved.
Rockalpha Limited is registered on the New Zealand Financial Service Providers Register(FSP: 1001454). Rockalpha Limited's Financial Service Providers registration can be verified on the Financial Service Providers Register. Rockalpha Limited is a member of the Insurance & Financial Services Ombudsman Scheme, an independent dispute resolution service provider. Rockalpha Limited is not licensed by a New Zealand regulator to provide the client money or property services, and Rockalpha Limited’s registration on the New Zealand register of financial service providers or membership of the Insurance & Financial Services Ombudsman Scheme does not mean that Rockalpha Limited is subject to active regulation or oversight by a New Zealand regulator.Rockalpha Limited is registered on the New Zealand Financial Service Providers Register(FSP: 1001454). Rockalpha Limited's Financial Service Providers registration can be verified on the Financial Service Providers Register. Rockalpha Limited is a member of the Insurance & Financial Services Ombudsman Scheme, an independent dispute resolution service provider.
Rockalpha Limited, operates from its Singapore headquarters at CapitaSky 808, 79 Robinson Road, Singapore 068897, with a regional office at Level 6, Core C, Cyberport 3, 100 Cyberport Road, Hong Kong.